Cancer drugmaker ArriVent follows on CG's heels with $175M IPO
BioPharma
Source: biopharmadive.com
Johnson Rybrevant News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Johnson Rybrevant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Johnson Rybrevant Today - Breaking & Trending Today
ArriVent's Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window
ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.
Source: medcitynews.com
Experimental Drug Wards Off Both Lung and Breast Cancer Progression in Trials
(Bloomberg) -- A new cancer medicine developed by AstraZeneca Plc and Daiichi Sankyo Co. seemed to fall short of investors’ expectations in partial results released early after a data leak at a medical conference. Most Read from BloombergBiden Vows Aid for Gaza, Backs Israel Over Hospital BlastHospital Blast Kills Hundreds as Israel, Hamas Trade BlameStocks Drop, Oil Climbs on Renewed Mideast Risks: Markets WrapUPenn Donors Pile Pressure on School as David Magerman Pulls SupportIsrael Latest: Bi
Source: yahoo.com
Takeda to Pull Lung Cancer Drug from Market After Failed Confirmatory Study
Takeda Pharmaceutical drug Exkivity failed the confirmatory study required of its 2021 accelerated approval. Our recap of other recent regulatory developments includes a partial clinical hold on a cancer drug, a Covid-19 vaccine authorization, and several drug approvals in the U.S. and beyond.
Source: medcitynews.com
J&J Drug Combo Shows Promise in Treating Lung Cancer
Johnson & Johnson's Rybrevant became the first medication for a particular subset of non-small cell lung cancer (NSCLC) in 2021.
Source: hngn.com